Advances in conditioning, graft-versus-host disease (GVHD) prophylaxis and antimicrobial
prophylaxis have improved the safety of allogeneic hematopoietic cell transplantation (HCT) …

The progress in aplastic anaemia (AA) management is one of success. Once an obscure
entity resulting in death in most affected can now be successfully treated with either …

Background Relapsed severe aplastic anaemia is a marrow failure disorder with high
morbidity and mortality. It is often treated with bone marrow transplantation at relapse post …

Fanconi anaemia is a challenging disease to manage, and haematopoietic stem-cell
transplantation (HSCT) is the treatment of choice for the haematological complications …

Haploidentical stem cell transplantation (haploSCT) has advanced to a common procedure
for treating patients with hematological malignancies and immunodeficiency diseases …

Poor graft function (PGF) is a life-threatening complication that occurs after transplantation
and has a poor prognosis. With the rapid development of haploidentical hematopoietic stem …

The COVID-19 pandemic has had a significant impact on medical practices, including the
delivery of allogeneic hematopoietic cell transplantation (HCT). In response, transplant …

Severe acute and chronic graft versus host disease (GVHD) remains a major cause of
morbidity and mortality after allogeneic hematopoietic cell transplantation. Historically, cord …

Allogenic hematopoietic cell transplantation (HCT) is the best curative approach for patients
with severe aplastic anemia (SAA). The outcomes of HCT from haploidentical family donors …

Aplastic anemia patients who are refractory to immunosuppressive therapy or with very low
neutrophil counts require allogeneic hematopoietic stem cell transplantation (HSCT) …